Photoreceptor layer thinning in idiopathic Parkinson's disease

Movement Disorders

Volumn 29, Issue 9, 2014, Pages 1163-1170

  Roth, Nicolas M ^a   Saidha, Shiv ^b,d   Zimmermann, Hanna ^a   Brandt, Alexander U ^a   Isensee, Justine ^a   Benkhellouf Rutkowska, Agnieszka ^a   Dornauer, Matthias ^a   Kühn, Andrea A ^a   Müller, Thomas ^c   Calabresi, Peter A ^d   Paul, Friedemann ^a,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BEAUMONT HOSPITAL   (Ireland)

^c St Joseph Hospital   (Germany)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Optical coherence tomography; Parkinson's disease; Retina, photoreceptor layer; Visual dysfunction

Indexed keywords

AGED; COLOR VISION; FEMALE; HUMAN; MALE; MIDDLE AGED; NERVE FIBER; NONPARAMETRIC TEST; OPTICAL COHERENCE TOMOGRAPHY; PARKINSON DISEASE; PATHOLOGY; PHOTORECEPTOR CELL; PHYSIOLOGY; PROCEDURES; RETINA; SEVERITY OF ILLNESS INDEX;

AGED; COLOR VISION; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE FIBERS; PARKINSON DISEASE; PHOTORECEPTOR CELLS, VERTEBRATE; RETINA; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84906046832     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25896     Document Type: Article

References (59)

1. Bodis-Wollner I. Retinopathy in Parkinson disease. J Neural Transm 2009;116:1493-1501. doi:10.1007/s00702-009-0292-z.
2. Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ. Ophthalmologic features of Parkinson's disease. Neurology. 2004;62:177-180.
3. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson's disease. Brain 2009;132:1128-1145. doi:10.1093/brain/awp068.
4. Djamgoz MB, Hankins MW, Hirano J, Archer SN. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res 1997;37:3509-3529. doi:10.1016/S0042-6989(97)00129-6.
5. Frederick JM, Rayborn ME, Laties AM, Lam DM, Hollyfield JG. Dopaminergic neurons in the human retina. J Comp Neurol 1982;210:65-79. doi:10.1002/cne.902100108.
6. Jackson GR, Owsley C. Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin 2003;21:709-728.
7. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992;42:887-890.
8. Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol 2002;59:1249-1252.
9. Bodis-Wollner I, Marx MS, Mitra S, Bobak P, Mylin L, Yahr M. Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity. Brain 1987;110:1675-1698.
10. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci 1990;31:2473-2475.
11. Hutton JT, Morris JL, Elias JW. Levodopa improves spatial contrast sensitivity in Parkinson's disease. Arch Neurol. 1993;50:721-724.
12. Nightingale S, Mitchell KW, Howe JW. Visual evoked cortical potentials and pattern electroretinograms in Parkinson's disease and control subjects. J Neurol Neurosurg Psychiatry 1986;49:1280-1287.
13. Peppe A, Stanzione P, Pierelli F, De Angelis D, Pierantozzi M, Bernardi G. Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials. Neurology 1995;45:1144-1148.
14. Tagliati M, Bodis-Wollner I, Yahr MD. The pattern electroretinogram in Parkinson's disease reveals lack of retinal spatial tuning. Electroencephalogr Clin Neurophysiol 1996;100:1-11.
15. Tartaglione A, Pizio N, Bino G, Spadavecchia L, Favale E. VEP changes in Parkinson's disease are stimulus dependent. J Neurol Neurosurg Psychiatry 1984;47:305-307.
16. Onofrj M, Ghilardi MF, Basciani M, Gambi D. Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. J Neurol Neurosurg Psychiatry 1986;49:1150-1159.
17. Maffei L, Fiorentini A, Bisti S, Holländer H. Pattern ERG in the monkey after section of the optic nerve. Exp Brain Res 1985;59:423-425.
18. Saidha S, Syc SB, Durbin MK, et al. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Multiple Sclerosis (Houndmills, Basingstoke, England). 2011. doi: 10.1177/1352458511418630.
19. Bock M, Brandt AU, Kuchenbecker J, et al. Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. Br J Ophthalmol 2011. doi: 10.1136/bjo.2010.193581.
20. Villoslada P, Cuneo A, Gelfand J, Hauser SL, Green A. Color vision is strongly associated with retinal thinning in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2012. doi: 10.1177/1352458511431972.
21. Altintaş O, Işeri P, Ozkan B, Caǧlar Y. Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease. Doc Ophthalmol. 2008;116(2):137-146. doi: 10.1007/s10633-007-9091-8.
22. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res 2004;44:2793-2797. doi: 10.1016/j.visres.2004.06.009.
23. Hajee ME, March WF, Lazzaro DR, et al. Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol 2009;127:737-741. doi: 10.1001/archophthalmol.2009.106.
24. Yavas GF, Yilmaz O, Küsbeci T, Oztürk F. The effect of levodopa and dopamine agonists on optic nerve head in Parkinson disease. Eur J Ophthalmol 2007;17:812-816.
25. La Morgia C, Barboni P, Rizzo G, et al. Loss of temporal retinal nerve fibers in Parkinson disease: a mitochondrial pattern? Eur J Neurol 2013;20:198-201. doi: 10.1111/j.1468-1331.2012.03701.x.
26. Rohani M, Langroodi AS, Ghourchian S, Falavarjani KG, SoUdi R, Shahidi G. Retinal nerve changes in patients with tremor dominant and akinetic rigid Parkinson's disease. Neurol Sci 2013;34:689-693. doi: 10.1007/s10072-012-1125-7.
27. Albrecht P, Müller A-K, Südmeyer M, et al. Optical coherence tomography in parkinsonian syndromes. PLoS ONE. 2012;7:e34891. doi: 10.1371/journal.pone.0034891.
28. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Retinal thickness in Parkinson's disease. Parkinsonism Relat Disord. 2011;17:431-436. doi: 10.1016/j.parkreldis.2011.03.004.
29. Tsironi EE, Dastiridou A, Katsanos A, et al. Perimetric and retinal nerve fiber layer findings in patients with Parkinson's disease. BMC Ophthalmol 2012;12:54. doi: 10.1186/1471-2415-12-54.
30. Schneider M, Müller H-P, Lauda F, et al. Retinal single-layer analysis in Parkinsonian syndromes: an optical coherence tomography study. J Neural Transm 2013. doi: 10.1007/s00702-013-1072-3.
31. Lee J-Y, Kim JM, Ahn J, Kim H-J, Jeon BS, Kim TW. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson's disease. Mov Disord 2013. doi: 10.1002/mds.25543.
32. Garcia-Martin E, Larrosa JM, Polo V, et al. Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration. Am J Ophthalmol 2013. doi: 10.1016/j.ajo.2013.09.028.
33. Satue M, Seral M, Otin S, et al. Retinal thinning and correlation with functional disability in patients with Parkinson's disease. Br J Ophthalmol 2013. doi: 10.1136/bjophthalmol-2013-304152.
34. Jimenez B, Ascaso FJ, Cristobal JA, Lopez del Val J. Development of a prediction formula of Parkinson disease severity by optical coherence tomography. Mov Disord 2014;29:68-74. doi: 10.1002/mds.25747.
35. Müller T, Woitalla D, Peters S, Kohla K, Przuntek H. Progress of visual dysfunction in Parkinson's disease. Acta Neurol Scand. 2002;105:256-260.
36. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
37. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-750. doi:10.1002/mds.10473.
38. Tewarie P, Balk L, Costello F, et al. The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment. PLoS ONE 2012;7:e34823. doi:10.1371/journal.pone.0034823.
39. Warner CV, Syc SB, Stankiewicz AM, et al. The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials. PLoS ONE 2011;6:e22947. doi:10.1371/journal.pone.0022947.
40. Saidha S, Syc SB, Ibrahim MA, et al. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 2011;134(Pt 2):518-533. doi:10.1093/brain/awq346.
41. Kinnear PR, Sahraie A. New Farnsworth-Munsell 100 hue test norms of normal observers for each year of age 5-22 and for age decades 30-70. Br J Ophthalmol 2002;86:1408-1411.
42. Smith VC, Pokorny J, Pass AS. Color-axis determination on the Farnsworth-Munsell 100-hue test. Am J Ophthalmol 1985;100:176-182.
43. Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Surg Radiol Anat 1988;10:137-144.
44. Wulle I, Wagner HJ. GABA and tyrosine hydroxylase immunocytochemistry reveal different patterns of colocalization in retinal neurons of various vertebrates. J Comp Neurol. 1990;296:173-178. doi:10.1002/cne.902960111.
45. Haug BA, Kolle RU, Trenkwalder C, Oertel WH, Paulus W. Predominant affection of the blue cone pathway in Parkinson's disease. Brain 1995;118:771-778.
46. Sartucci F, Orlandi G, Lucetti C, et al. Changes in pattern electroretinograms to equiluminant red-green and blue-yellow gratings in patients with early Parkinson's disease. J Clin Neurophysiol 2003;20:375-381.
47. Witkovsky P. Dopamine and retinal function. Doc Ophthalmol 2004;108:17-40.
48. Witkovsky P, Gábriel R, Krizaj D. Anatomical and neurochemical characterization of dopaminergic interplexiform processes in mouse and rat retinas. J Comp Neurol 2008;510:158-174. doi:10.1002/cne.21784.
49. Müller T, van Laar T, Cornblath DR, et al. Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 2013;19:501-507; discussion, 501. doi:10.1016/j.parkreldis.2013.02.006.
50. Müller T, Przuntek H, Kuhlmann A. Loss of color vision during long-term treatment with pramipexole. J Neurol. 2003;250:101-102. doi:10.1007/s00415-003-0915-5.
51. Müller T, Kuhn W, Büttner T, et al. Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson's disease. J Neurol. 1998;245:659-664.
52. Müller T, Meisel M, Russ H, Przuntek H. Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients. J Neurol Sci. 2003;213:61-65.
53. Adam CR, Shrier E, Ding Y, Glazman S, Bodis-Wollner I. Correlation of inner retinal thickness evaluated by spectral-domain optical coherence tomography and contrast sensitivity in Parkinson disease. J Neuroophthalmol 2013;33:137-142. doi: 10.1097/WNO.0b013e31828c4e1a.
54. Cubo E, Tedejo RP, Rodriguez Mendez V, López Peña MJ, Trejo Gabriel Y, Galán JM. Retina thickness in Parkinson's disease and essential tremor. Mov Disord. 2010;25:2461-2462. doi:10.1002/mds.23215.
55. Aaker GD, Myung JS, Ehrlich JR, Mohammed M, Henchcliffe C, Kiss S. Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography. Clin Ophthalmol 2010;4:1427-1432. doi: 10.2147/OPTH.S15136.
56. Shrier EM, Adam CR, Spund B, Glazman S, Bodis-Wollner I. Interocular asymmetry of foveal thickness in Parkinson disease. J Ophthalmol 2012;2012:728457. doi: 10.1155/2012/728457.
57. Satue M, Garcia-Martin E, Fuertes I, et al. Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson's disease patients. Eye (Lond) 2013;27:507-514. doi: 10.1038/eye.2013.4.
58. Garcia-Martin E, Satue M, Fuertes I, et al. Ability and reproducibility of Fourier-domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson's disease. Ophthalmology 2012;119:2161-2167. doi: 10.1016/j.ophtha.2012.05.003.
59. Kirbas S, Turkyilmaz K, Anlar O, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in patients with Alzheimer disease. J Neuroophthalmol 2013;33:58-61. doi: 10.1097/WNO.0b013e318267fd5f.